A recent report on EP300, which was published toward the end of our study, further supports this observation (Rubio et al., 2023), as do the in vivo observations uncovered during our target efficacy analysis, showing that EP300 knockout or knockdown can reduce liver fibrosis and its underlying processes (Supplementary Material S2). The gene discussed is EP300; the disease is Hepatic fibrosis.